Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #172 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Gujarat Inject (Kerala) Ltd. (this stock) | 14 | 4.6 | 16.6% | -61.9% | — | 69 | 99 | 63 |
Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.
Jun 2026 quarterly revenue is Rs 12 Cr, up 414.5% YoY.
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 12 | 2 | 1 | ₹0.8600 |
| March 31, 2026 | 31 | 2 | 2 | ₹1.1200 |
| Dec. 31, 2025 | 2 | 0 | 0 | ₹0.0300 |
| Sept. 30, 2025 | 2 | 0 | — | ₹0.0500 |
| June 30, 2025 | 2 | 0 | — | ₹0.0500 |
| March 31, 2025 | 4 | 0 | 0 | ₹0.0500 |
| Dec. 31, 2024 | 3 | 0 | 0 | ₹0.1400 |
| Sept. 30, 2024 | 9 | 1 | 1 | ₹0.0500 |
| June 30, 2024 | 3 | 0 | 0 | ₹0.0800 |
| March 31, 2024 | 5 | 0 | 0 | ₹0.0300 |
| Dec. 31, 2023 | 0 | 0 | 0 | ₹0.0100 |
| Sept. 30, 2023 | 0 | 0 | 0 | ₹0.0300 |
| June 30, 2023 | 0 | 0 | 0 | ₹0.0600 |
| Indicator | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total income (before exceptional items) | — | — | 2 | 2 | — | 4 | 3 | 9 | — | — | 0 | 0 | — |
| Operating revenue | 12 | 31 | 2 | 2 | 2 | 4 | 3 | 9 | 3 | 5 | 0 | 0 | 0 |
| Other income | — | — | 0 | 0 | — | 0 | 0 | 0 | — | — | 0 | 0 | — |
| Operating expenses | 11 | 28 | 2 | 2 | 2 | 4 | — | 8 | — | — | — | — | — |
| Operating profit | 2 | 2 | -0 | 0 | 0 | 0 | — | 1 | — | — | — | — | — |
| Operating profit margin | 13.6% | 7.4% | -5.4% | 2.0% | 4.0% | 2.1% | — | 6.3% | — | — | — | — | — |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | — | — | — | — | — |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 | — | — | — |
| Exceptional items, gain / (loss) | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Profit before tax | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 1 | 2 | 0 | — | — | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| EPS | 0.86 | 1.12 | 0.03 | 0.05 | 0.05 | 0.05 | 0.14 | 0.05 | 0.08 | 0.03 | 0.01 | 0.03 | 0.06 |
| Net profit (TTM) | — | — | — | — | — | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| EPS (TTM) | 2.06 | 1.25 | 0.18 | 0.29 | 0.29 | 0.32 | 0.30 | 0.17 | 0.15 | 0.13 | 0.11 | — | — |
Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.
| Indicator | CAGR 3Y | CAGR 5Y | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 20 | Mar 19 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total income (before exceptional items) | — | — | — | — | — | — | 0† | — | — | 0† |
| Operating revenue | 494.3% | — | 36† | 19† | 6† | 0† | 0† | — | — | 0† |
| Other income | — | — | — | — | — | — | 0† | — | — | 0† |
| Operating expenses | — | — | 34† | — | — | — | — | — | — | — |
| Operating profit | — | — | 2† | — | — | — | — | — | — | — |
| Operating profit margin | — | — | 6.4%† | — | — | — | — | — | — | — |
| Depreciation | — | — | 0† | — | — | — | — | — | — | — |
| Interest | — | — | 0† | — | — | — | — | — | — | — |
| Exceptional items, gain / (loss) | — | — | 0† | 0† | 0† | 0† | 0† | 0† | 0† | 0† |
| Profit before tax | 257.1% | — | 3† | 1† | 0† | 0† | — | — | — | — |
| Tax | — | — | 1† | 0† | 0† | 0† | — | — | — | — |
| Net profit | — | — | — | 1† | 0† | 0† | — | — | — | — |
| EPS | — | — | 1.25† | 0.32† | 0.13† | — | — | — | — | — |
† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.
| Ratio | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 20 | Mar 19 | Mar 18 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | 6.4%† | — | — | — | — | — | — | — |
| EBIT margin | 6.9%† | — | — | — | — | — | — | — |
| PBT margin | 6.9%† | 6.6%† | 1.8%† | 31.8%† | — | — | — | — |
| Net margin | — | 5.3%† | 1.5%† | 23.1%† | — | — | — | — |
| Interest coverage | 12521.00x† | — | — | — | — | — | — | — |
| Dividend payout | — | — | — | — | — | — | — | — |
| Earnings retention | — | — | — | — | — | — | — | — |
| Current ratio | 0.47x | 4.73x | — | — | — | — | — | — |
| Quick ratio | 0.47x | 4.73x | — | — | — | — | — | — |
| Debt to equity | 0.00x | 0.00x | — | — | — | — | — | — |
| Return on equity | — | 10.2%† | — | — | — | — | — | — |
| Return on assets | — | 8.5%† | — | — | — | — | — | — |
| Return on capital employed | 21.2%† | — | — | — | — | — | — | — |
| Asset turnover | 0.99x† | 1.59x† | — | — | — | — | — | — |
Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 21 | -21 | 0 | 21 | 0 |
| March 31, 2025 | -4 | 0 | 1 | 0 | -4 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 37 | 12 | -3 | 0 | 0 | 12 | 25 | 1 | 0 | 0 |
| March 31, 2025 | 12 | 10 | -5 | 0 | 0 | 9 | 2 | 0 | 0 | 0 |
Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.
